Oculis Holding AG (NASDAQ: OCS) Advances Eye Disease Treatments, Maintains Buy Rating
H.C. Wainwright has reiterated its Buy rating for Oculis Holding AG, with shares trading at $7.49. Oculis is progressing with clinical trials for two key drug candidates: Privosegtor for acute optic neuritis and licaminlimab for dry eye disease. Initial results from the PREDICT-1 registrational…